COMBINATION THERAPY INVOLVING EGF INHIBITORS

摘要

Provided is the use of an inhibitor of HB-EGF and an inhibitor of AREG in the preparation of a medicament formulated for simultaneous or sequential use in the combination treatment of neoplastic disease; wherein, in said combination treatment, said inhibitor of HBEGF and said inhibitor of AREG act synergistically; wherein said inhibitor of HB-EGF is an antibody molecule which binds said HB-EGF or a nucleic acid molecule which inhibits expression of HB-EGF; and wherein said inhibitor of AREG is an antibody molecule which binds AREG or a nucleic acid molecule which inhibits expression of AREG. Further provided are compositions comprising the two inhibitors and specific amino acid sequences of the antibodies therein.